There are currently 31 active clinical trials seeking participants for Cirrhosis research studies. The states with the highest number of trials for Cirrhosis participants are California, Virginia, Texas and New York.
Remote Electrical Stimulation for Pain and Depression Treatment in Cirrhosis
NCT06932783
Recruiting
This study is being done to better understand how the study team can treat pain for people with cirrhosis and depression. Enrolled participants on this feasibility study will be randomized to Transcutaneous Electrical Acustimulation (TEA) or sham TEA.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/28/2025
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Cirrhosis
Register for Updates
HepHospital: A Pilot Trial of a Hepatology Home Hospital Intervention for Patients With Advanced Liver Disease
NCT05205954
Recruiting
This research study is evaluating a program that entails a healthcare at home intervention for people with advanced liver disease.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/21/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts +1 locations
Conditions: Cirrhosis, End Stage Liver DIsease, Liver Cirrhosis, Liver Disease Chronic
Register for Updates
LiverPAL: A Trial of Inpatient Palliative Care for Patients With Advanced Liver Disease
NCT05998330
Recruiting
The goal of this clinical trial is to evaluate whether early integration of palliative care in the care of hospitalized patients with advanced liver disease (AdvLD) can improve patients' quality of life, physical symptoms, mood, and serious illness communication. Palliative care is a medical specialty focused on lessening (or "palliating") symptoms and assisting in coping with serious illness.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/10/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Liver Disease Chronic, End Stage Liver DIsease, Cirrhosis, Cirrhosis, Liver, Advanced Cirrhosis
Register for Updates
ALTUS: Performance of a Multi- Target Hepatocellular Carcinoma (HCC) Test in Subjects With Increased Risk
NCT05064553
Recruiting
The primary objective is to assess overall sensitivity and specificity of Oncoguard™ Liver for hepatocellular cancer (HCC) detection in a surveillance population.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/17/2025
Locations: Arizona Health Research, Chandler, Arizona +71 locations
Conditions: Hepatocellular Carcinoma, Hepatocellular Cancer, Hepatitis B, Cirrhosis, Liver Cancer
Register for Updates
Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434
NCT05484206
Recruiting
In this study, a single dose of VIR-2218 up to 200 mg SC or VIR-3434 at 300 mg SC monotherapy or a combination of VIR-2218 and VIR-3434 will be administered to assess the pharmacokinetic (PK) exposure, safety, and tolerability of VIR-2218 and VIR-3434 in participants with cirrhosis and Hepatic Impairment, defined using the Child-Pugh-Turcotte (CPT) categorization.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
06/10/2025
Locations: Inland Empire Clinical Trials, Rialto, California +4 locations
Conditions: Hepatic Impairment, Cirrhosis
Register for Updates
Droxidopa to Increase Mean Arterial Pressure in Decompensated Cirrhosis Patients With Acute Kidney Injury
NCT06937307
Recruiting
This study tests whether a medication called droxidopa can help improve blood flow to the kidneys in people with liver cirrhosis who develop kidney problems while in the hospital. When someone with cirrhosis experiences kidney injury, having better blood pressure can help their kidneys recover. Droxidopa is an oral medication that may help raise blood pressure without requiring intensive care or invasive treatments. The study will compare droxidopa to a placebo (inactive pill) in 75 people hospi... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
06/03/2025
Locations: Columbia University Irving Medical Center, New York, New York
Conditions: Acute Kidney Injury, Cirrhosis, Decompensated Cirrhosis of Liver
Register for Updates
Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States
NCT05832229
Recruiting
This is a double-blind, phase 2 study to evaluate safety and efficacy of rosuvastatin in comparison to placebo after 2 years in patients with compensated cirrhosis.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/21/2025
Locations: University of California San Diego NAFLD Research Center, La Jolla, California +12 locations
Conditions: Cirrhosis, Cirrhosis, Liver, Cirrhosis Early, Cirrhosis Due to Hepatitis B, Cirrhosis Advanced, Cirrhosis Infectious, Cirrhosis Alcoholic, Cirrhosis Due to Hepatitis C
Register for Updates
Liver Cirrhosis Network Cohort Study
NCT05740358
Recruiting
Liver Cirrhosis Network (LCN) Cohort Study is an observational study designed to identify risk factors and develop prediction models for risk of decompensation in adults with liver cirrhosis. LCN Cohort Study involves multiple institutions and an anticipated 1200 participants. Enrolled participants will have study visits every 6 months (180 days), with opportunities to complete specific visit components via telehealth or remotely. Visits will include collection of questionnaire data and the in-p... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2025
Locations: University of California San Diego NAFLD Research Center, La Jolla, California +13 locations
Conditions: Cirrhosis, Cirrhosis, Liver, Cirrhosis Early, Cirrhosis Due to Hepatitis B, Cirrhosis Advanced, Cirrhosis Infectious, Cirrhosis Alcoholic, Cirrhosis, Biliary, Cirrhosis Cryptogenic, Cirrhosis Due to Hepatitis C, Cirrhosis Due to Primary Sclerosing Cholangitis, Autoimmune Hepatitis
Register for Updates
Technology Enabled Strategies to Promote Treatment Adherence in Liver Transplant
NCT05260268
Recruiting
Liver transplantation is increasingly performed for older adults with multiple comorbidities. Medication adherence is key to maintaining proper function of the transplanted liver and optimize health; however, adhering to post-transplant treatment is complex. This trial will study how available technology combined with transplant center resources and caregiver support can optimize medication adherence, quality of life, and health outcomes among new liver transplant recipients at 3 centers.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/13/2025
Locations: University of Miami, Miami, Florida +2 locations
Conditions: Liver Transplant; Complications, Cirrhosis, End Stage Liver DIsease, Medication Adherence
Register for Updates
Intestinal Microbiota Transplant in Alcohol-Associated Liver Disease
NCT05548452
Recruiting
The purpose of this research study is to test the safety, tolerability, and effectiveness of the capsules that contain bacteria from healthy individuals when used to treat alcohol craving and drinking.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/05/2025
Locations: Hunter Holmes McGuire VA Medical Center, Richmond, Virginia +1 locations
Conditions: Liver Disease; Alcohol-Related, Cirrhosis, Alcohol Use Disorder
Register for Updates
Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis
NCT05201404
Recruiting
This is a clinical trial in patients with advanced hepatocellular carcinoma (HCC) and Child-Pugh Class B7 (CPB7) cirrhosis whose disease has progressed on at least 1st-line therapy. The trial will evaluate the efficacy and safety of namodenoson as compared to placebo.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/28/2025
Locations: Site 881, Dallas, Texas +31 locations
Conditions: Hepatocellular Carcinoma, Cirrhosis
Register for Updates
Empagliflozin in Patients With Cirrhosis and Ascites
NCT05726032
Recruiting
A proof-of-concept placebo-controlled trial to explore the acute and 14-day effects of empagliflozin on natriuresis and total body water in patients with cirrhosis and ascites. We will additionally investigate its effect on neurohumoral activation, and renal hemodynamics.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/25/2025
Locations: Yale University, New Haven, Connecticut
Conditions: Cirrhosis, Liver Failure
Register for Updates